In January 2019, Russia exported 1.53 bln RUB worth of pharmaceutical drugs (customs duties included, exports to the EEU countries excluded), which is in monetary terms 73.3% higher than that of January 2018. In physical terms, the dynamics are +46.4% (31.0 mln units.)

However, the high dynamics are due not to the growing export volumes, but to the lower activity of exporting companies in January 2018. Russia exports not only Russian-made drugs, but also pre-imported ones. In January 2019, the list of exporting companies had 195 names, against 211 in 2018. The product list has also gone down by 20, to 804 trademarks.

Among the top 15 Russian companies with the highest export volume, Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products of RAS and Biocad have the highest dynamics for the period. The former’s exports have risen by nearly 252 times in monetary terms, with Yellow Fever Vaccine to the dynamics the most (a 599 times increase.) The latter’s exports have increased by 197 times, with anti-tumor Bevacizumab contributing to the dynamics.

Nearmedic Plus also has good dynamics in monetary terms; the export of its anti-viral Kagocel has increased by 25 times in monetary terms. With the flu season in full swing, it is no wonder Kagocel placed 4th in the respective trademark rankings. The product was exported to the following 5 directions: Moldova (72% of the total export), Georgia (20%), Ukraine (8%), Tadzhikistan (0.12%) and Abkhazia (0.05%.)

Dynamics and volume of pharmaceutical drug export from Russia, bln RUB (EEU countries excluded) (2016 – 2018, January 2019)